Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

About Karyopharm Therapeutics

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KPTI
  • CUSIP:
Key Metrics:
  • Previous Close: $6.92
  • 50 Day Moving Average: $7.23
  • 200 Day Moving Average: $7.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.25
  • P/E Growth: 0.16
  • Market Cap: $249.04M
  • Outstanding Shares: 35,989,000
  • Beta: 4.33
Additional Links:
Companies Related to Karyopharm Therapeutics:

Analyst Ratings

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $17.09 (146.98% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetDetails
8/18/2016HC WainwrightInitiated CoverageBuy$15.00View Rating Details
8/6/2016Canaccord GenuitySet Price TargetBuy$20.00View Rating Details
8/4/2016WedbushReiterated RatingOutperform$14.00View Rating Details
6/27/2016Robert W. BairdInitiated CoverageOutperform$16.00View Rating Details
6/27/2016Leerink SwannReiterated RatingBuyView Rating Details
6/1/2016Jefferies GroupDowngradeBuy -> Hold$14.00View Rating Details
5/27/2016Raymond James Financial Inc.Initiated CoverageOutperform$13.00View Rating Details
3/15/2016Bank of America Corp.DowngradeNeutral -> Underperform$26.00 -> $11.00View Rating Details
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00View Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00View Rating Details
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00View Rating Details
3/17/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$53.00View Rating Details
11/5/2014Barrington ResearchInitiated CoverageBuy$54.00View Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216($0.76)($0.84)ViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)ViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)ViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)ViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)ViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)ViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)ViewListenView Earnings Details
11/10/2014Q314($0.52)($0.61)ViewN/AView Earnings Details
8/7/2014Q214($0.50)($1.02)ViewN/AView Earnings Details
5/7/2014($0.47)($0.46)ViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
Current Year EPS Consensus Estimate: $-3.26 EPS
Next Year EPS Consensus Estimate: $-3.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.79)($0.73)($0.75)
Q2 20163($0.76)($0.73)($0.74)
Q3 20163($0.83)($0.75)($0.79)
Q4 20163($0.84)($0.76)($0.80)
Q1 20171($0.63)($0.63)($0.63)
Q2 20171($0.62)($0.62)($0.62)
Q3 20171($0.63)($0.63)($0.63)
Q4 20171($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
DateHeadline
live-pr.com logoNewly released market study: Karyopharm Therapeutics, Inc. (KPTI) - Financial and Strategic SWOT Analysis Review (NASDAQ:KPTI)
www.live-pr.com - August 23 at 10:17 AM
News IconNoteworthy Monday Option Activity: KPTI, SHLD, MXWL (NASDAQ:KPTI)
www.stockoptionschannel.com - August 22 at 5:55 PM
News IconWhat is Wall Street Saying About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Post News (NASDAQ:KPTI)
www.kentuckypostnews.com - August 19 at 5:51 PM
investornewswire.com logoWill Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Hit $18 Price Target? - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - August 19 at 5:51 PM
streetinsider.com logoPre-Open Stock Movers 8/18: (SEMI) (CIE) (RPTP) Higher; (EARS) (CERU) (PTLA) Lower (NASDAQ:KPTI)
www.streetinsider.com - August 19 at 8:53 AM
finance.yahoo.com logoCoverage initiated on Karyopharm Therapeutics by H.C. Wainwright (NASDAQ:KPTI)
finance.yahoo.com - August 18 at 5:54 PM
realistinvestor.com logoAnalysts See Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Reporting EPS Of $-0.7 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - August 16 at 9:08 AM
finance.yahoo.com logoKARYOPHARM THERAPEUTICS INC. Financials (NASDAQ:KPTI)
finance.yahoo.com - August 13 at 5:41 PM
capitalcube.com logoETF’s with exposure to Karyopharm Therapeutics, Inc. : August 8, 2016 (NASDAQ:KPTI)
www.capitalcube.com - August 8 at 6:04 PM
finance.yahoo.com logoEdited Transcript of KPTI earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:KPTI)
finance.yahoo.com - August 5 at 6:01 PM
capitalcube.com logoKaryopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:KPTI)
www.capitalcube.com - August 5 at 6:01 PM
globenewswire.com logoKaryopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress (NASDAQ:KPTI)
globenewswire.com - August 4 at 8:57 AM
twst.com logoKaryopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress (NASDAQ:KPTI)
www.twst.com - August 4 at 8:57 AM
sg.finance.yahoo.com logoKaryopharm Therapeutics posts 2Q loss (NASDAQ:KPTI)
sg.finance.yahoo.com - August 4 at 8:57 AM
publicnow.com logoKaryopharm to Present at Upcoming Investor Conferences (NASDAQ:KPTI)
www.publicnow.com - August 3 at 9:05 AM
investornewswire.com logoCan Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Keep Up with Analyst Expectations? - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 31 at 5:32 PM
investornewswire.com logoCan Shares Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Hit $20? - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 29 at 6:01 PM
publicnow.com logoKaryopharm to Report Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:KPTI)
www.publicnow.com - July 28 at 8:08 AM
publicnow.com logoKaryopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting (NASDAQ:KPTI)
www.publicnow.com - July 27 at 4:28 PM
publicnow.com logoKaryopharm Announces Phase 1b Selinexor Sarcoma Data Published in Journal of Clinical Oncology (NASDAQ:KPTI)
www.publicnow.com - July 27 at 7:38 AM
finance.yahoo.com logo7:34 am Karyopharm Therapeutics announces publication of data from its Phase 1b clinical trial evaluating KPT-330 in patients with advanced refractory bone or soft tissue sarcoma in the Journal of Clinical Oncology (NASDAQ:KPTI)
finance.yahoo.com - July 27 at 7:34 AM
investornewswire.com logoWill Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surprise Analysts? - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 26 at 6:06 PM
investornewswire.com logoIs $20 Price Target Attainable For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 24 at 10:10 AM
equities.com logoKaryopharm Therapeutics Inc. (KPTI) Drops 6.82% on July 19 - Equities.com (NASDAQ:KPTI)
www.equities.com - July 21 at 12:01 PM
News IconWhat Next for Karyopharm Therapeutics Inc Stock After Today's Huge Decline? - Consumer Eagle (NASDAQ:KPTI)
www.consumereagle.com - July 20 at 8:51 AM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:KPTI)
www.engelwooddaily.com - July 20 at 8:51 AM
News IconTrading Performance and Target Watch for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Press Telegraph (NASDAQ:KPTI)
presstelegraph.com - July 18 at 11:10 AM
investornewswire.com logoStrong Sell Calls For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 0 - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 16 at 5:33 PM
equities.com logoKaryopharm Therapeutics Inc. (KPTI) Jumps 6.12% on July 15 - Equities.com (NASDAQ:KPTI)
www.equities.com - July 16 at 5:33 PM
News IconKaryopharm Therapeutics Incorporated (NASDAQ:KPTI) Shorted Shares Decreased By 4.69% - Consumer Eagle (NASDAQ:KPTI)
www.consumereagle.com - July 15 at 9:53 AM
news.cmlviz.com logoKaryopharm Therapeutics Inc Realized Volatility Hits Extreme Level - CML News (NASDAQ:KPTI)
news.cmlviz.com - July 15 at 9:53 AM
News IconAnalyst Target and Average Rating Watch: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Press Telegraph (NASDAQ:KPTI)
presstelegraph.com - July 14 at 9:28 AM
kcregister.com logoStock Alert: Alnylam Pharmaceuticals (NASDAQ:ALNY), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), Western ... - KC Register (NASDAQ:KPTI)
www.kcregister.com - July 12 at 10:15 AM
News IconWere Analysts Bullish Karyopharm Therapeutics Inc (NASDAQ:KPTI) This Week? - Press Telegraph (NASDAQ:KPTI)
presstelegraph.com - July 10 at 10:09 AM
news.cmlviz.com logoKaryopharm Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:KPTI)
news.cmlviz.com - July 8 at 5:59 PM
fiscalstandard.com logoBroker Outlook For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Fiscal Standard (NASDAQ:KPTI)
www.fiscalstandard.com - July 8 at 5:59 PM
investornewswire.com logoIs $20 Within Reach For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 8 at 5:59 PM
publicnow.com logoKaryopharm to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:KPTI)
www.publicnow.com - July 6 at 7:41 AM
finance.yahoo.com logoKaryopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference (NASDAQ:KPTI)
finance.yahoo.com - July 6 at 7:30 AM
News IconHow Many Karyopharm Therapeutics Inc (NASDAQ:KPTI)'s Analysts Are Bullish? - Press Telegraph (NASDAQ:KPTI)
presstelegraph.com - July 3 at 5:26 PM
News IconIs Karyopharm Therapeutics Inc's Fuel For Real? The Stock Just Increased Again - Engelwood Daily (NASDAQ:KPTI)
www.engelwooddaily.com - July 2 at 8:45 AM
investornewswire.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Reach Highs Of $20 - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - July 2 at 8:45 AM
fiscalstandard.com logoRecently Issued Stock Ratings For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Fiscal Standard (NASDAQ:KPTI)
www.fiscalstandard.com - July 2 at 8:45 AM
breakingfinancenews.com logoKaryopharm Therapeutics (NASDAQ:KPTI) target price bumped up to $16 as covered today by Robert W. Baird (NASDAQ:KPTI)
breakingfinancenews.com - June 28 at 10:45 AM
investornewswire.com logoStrong Sell Calls Recommendations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 0 - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - June 25 at 9:41 AM
4-traders.com logoKaryopharm Therapeutics : Initiates Phase 1 Clinical Trial with KPT-9274 (NASDAQ:KPTI)
www.4-traders.com - June 23 at 6:16 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Commences KPT-9274 Phase 1 in Adv. Solid Malignancies or NHL (NASDAQ:KPTI)
www.streetinsider.com - June 23 at 6:16 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Commences KPT-9274 Phase 1 in Adv. Solid Malignancies or NHL - StreetInsider.com (NASDAQ:KPTI)
www.streetinsider.com - June 22 at 10:31 AM
finance.yahoo.com logoKaryopharm Commences First Stage Clinical Study With KPT-9274 (NASDAQ:KPTI)
finance.yahoo.com - June 22 at 10:26 AM
publicnow.com logoKaryopharm Initiates Phase 1 Clinical Trial with KPT-9274 (NASDAQ:KPTI)
www.publicnow.com - June 22 at 7:39 AM

Social

Karyopharm Therapeutics (NASDAQ:KPTI) Chart for Friday, August, 26, 2016


Last Updated on 8/26/2016 by MarketBeat.com Staff